VX-509 (Decernotinib)-Mediated CYP3A Time-dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions

Data Supplement

Files in this Data Supplement:

• Supplemental Figures -

  Supplemental Figure 1 - VX-509 and metabolite M3 numbering scheme and peak assignments

  Supplemental Figure 2 - Proton NMR spectra for VX-509 and metabolite M3

  Supplemental Figure 3 - Proton NMR spectra for VX-509 and metabolite M3 (region 5-10 ppm)

  Supplemental Figure 4 - Proton NMR spectra for VX-509 and metabolite M3 (region 0-5 ppm)

  Supplemental Figure 5 - COSY spectrum for VX-509

  Supplemental Figure 6 - COSY spectrum for metabolite M3

  Supplemental Figure 7 - 13C NMR spectra for VX-509 and metabolite M3

  Supplemental Figure 8 - 13C NMR spectra for VX-509 and metabolite M3 (region 90-190 ppm)

  Supplemental Figure 9 - 13C NMR spectra for VX-509 and metabolite M3 (region 0-90 ppm)

  Supplemental Figure 10 - 13C DEPT135 spectra for VX-509 and metabolite M3

  Supplemental Figure 11 - HSQC spectrum for VX-509

  Supplemental Figure 12 - HSQC spectrum for metabolite M3

  Supplemental Figure 13 - HMBC spectrum for VX-509

  Supplemental Figure 14 - HMBC spectrum for metabolite M3